Antibodies commonly contain hydrophobic residues within their complementarity-determining regions (CDRs) that mediate binding to target antigens. Unfortunately, hydrophobic CDRs can also promote antibody aggregation, which is especially concerning for therapeutic antibodies due to the immunogenicity of antibody aggregates. Here we investigate how the sequences of CDRs within singledomain (V H ) antibodies specific for the Alzheimer's amyloid b peptide can be engineered to resist aggregation without reducing binding affinity. We find that domain antibodies containing clusters of hydrophobic residues within their third CDR (CDR3) are prone to aggregate within days at 258 8 8 8 8C and minutes above 708 8 8 8 8C. However, inserting two or more negatively charged residues at each edge of CDR3 potently suppresses antibody aggregation without altering binding affinity. We also find that inserting charged mutations at one edge of CDR3 (N-or C-terminal) prevents aggregation, but only if such mutations are located at the edge closest to most hydrophobic portion of CDR3. In contrast, charged mutations outside of CDR3 fail to suppress aggregation. Our findings demonstrate that the sequence of CDR loops can be engineered in a systematic manner to improve antibody solubility without altering binding affinity or specificity.
Introduction
The sequence and conformation of complementaritydetermining region (CDR) loops determine the binding affinity and specificity of antibodies to target antigens. Hydrophobic residues are common within these peptide loops and are central to antibody-antigen recognition (Mian et al., 1991; Padlan, 1994; Davies and Cohen, 1996; Sundberg et al., 2000; Fellouse et al., 2005 Fellouse et al., , 2006 . However, solvent-exposed hydrophobic residues can also mediate antibody self-association and, in some cases, antibody aggregation (Pepinsky et al., 2010; Wu et al., 2010; Perchiacca et al., 2011) . This problem is amplified for antibodies that must be formulated at extremely high concentrations (.50 mg/ml)-conditions that favor aggregation due to close proximity between antibody molecules-to achieve suitable therapeutic doses in relatively small volumes (,2 ml) necessary for subcutaneous delivery (Frokjaer and Otzen, 2005; Dani et al., 2007; Shire, 2009; Lowe et al., 2011) .
There are multiple protein engineering strategies to improve antibody solubility without reducing antibodybinding affinity ( (Perchiacca and Tessier, 2012b) and references therein). One approach is to introduce solubilizing amino acids (e.g. charged residues) and/or oligosaccharides outside of the CDRs in the variable and constant regions (Nieba et al., 1997; Tan et al., 1998; Jespers et al., 2004b; Conrath et al., 2005; Tanha et al., 2006; Miller et al., 2009; Pepinsky et al., 2010; Wu et al., 2010; Miklos et al., 2012) . A more direct approach is to insert solubilizing mutations into the CDRs, although a concern with this approach is that such mutations may reduce binding affinity. We recently reported that a single-domain (V H ) antibody-which is a germline V H 3 variant without a known binding partner (Jespers et al., 2004a,b) -contains an aggregation hotspot within its first CDR (CDR1) (Perchiacca et al., 2011) . We identified a triad of charged mutations (replacement of residues 31-SYA-33 with 31-DED-33) within CDR1 that potently suppressed aggregation of the domain antibody (dAb), although these substitution mutations in the middle of CDR1 are expected to generally reduce binding affinity. However, we also identified a single-charged mutation (replacement of phenylalanine with aspartate at position 29) immediately adjacent to the hydrophobic CDR1 that potently prevented antibody aggregation even when the dAb was heated to 958C. Importantly, this mutation is outside of CDR1 and the original residue at position 29 ( phenylalanine) is conserved across diverse human antibodies (Chothia et al., 1992; Tomlinson et al., 1992) , revealing that it is typically not involved in the antibody paratope.
These findings led us to hypothesize that the solubility of antibodies could be systematically increased for antibody variants with hydrophobic CDR loops by inserting charged residues at the edges of loops containing aggregation hotspots. We also hypothesized that such solubilizing insertion mutations at the edges of CDRs would either have minimal impact on antibody-binding affinity or could be introduced into synthetic libraries to select antibody variants with binding affinities similar to antibodies lacking such charged residues at the edges of CDRs. As a first step towards evaluating these hypotheses, we have investigated the impact of charged insertion mutations at the edges of the third CDR (CDR3) of single-domain (V H ) antibodies on their solubility and binding affinity to the Alzheimer's amyloid-b (Ab) peptide (Perchiacca et al., 2012a) . The wild-type (uncharged) dAbs present hydrophobic Ab peptide segments (10 residues) within CDR3, and they bind to aggregated Ab conformers ( prefibrillar oligomers and amyloid fibrils) with nanomolar-binding affinity. We refer to these dAbs as gammabodies for Grafted AMyloid-Motif AntiBODIES. Here we report how Ab dAbs can be engineered to resist aggregation without altering their binding affinity by introducing charged insertion mutations at the edges of CDR3.
Materials and methods
Antibody engineering, expression and purification DNA fragments encoding the wild-type and charged dAbs were created using polymerase chain reaction-based gene synthesis (Hoover and Lubkowski, 2002) . The genes were synthesized with a PelB leader sequence for periplasmic expression, and C-terminal peptide tags for detection (3Â flag tag) and purification (7Â His-tag). The restriction sites BamHI and NotI were inserted at the edges of CDR3. The dAb gene was ligated into a pET-17b plasmid (Novagen) between the NdeI and XhoI restriction sites. All CDR3 variants were created by ligating pairs of synthetic primers between the BamHI and NotI restriction sites.
The dAbs were expressed in bacteria (BL21(DE3)pLysS, Stratagene) for 48 h at 308C using autoinduction media (Studier, 2005) supplemented with ampicillin (100 mg/ml) and chloramphenicol (35 mg/ml). The cells were then pelleted and discarded without lysis. The supernatant was collected and incubated overnight with 2.5 ml of nickel beads (Ni-NTA, Pierce) at 158C with mild agitation. The beads were then collected, and the protein was eluted ( pH 3, phosphate-buffered saline (PBS)), and neutralized ( pH 7). The protein purity was evaluated using sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis (12% acrylamide tris-glycine gel, Invitrogen), and the protein concentration was measured using the bicinchoninic acid (BCA) protein assay (Pierce).
Circular dichroism measurements
Circular dichroism (CD) spectra and thermal unfolding curves (10 mM antibody) were recorded using a Jasco 815 Spectrometer (0.5 nm bandwidth, 1 s integration time) in the far-UV region (200 -260 nm) . For thermal unfolding analysis, the heating rate was 18C/min and the ellipticity was monitored at 235 nm. The fraction of folded protein was calculated as (Q T -Q U )/(Q F -Q U ), where Q T is the ellipticity at a given temperature, Q U is the ellipticity of the fully unfolded state and Q F is the ellipticity of the fully folded state of the protein (Greenfield, 2006) .
Tryptophan fluorescence measurements
The tryptophan fluorescence (l ex ¼ 280 nm, l em ¼ 350 nm) of each dAb was monitored using a Fluorolog-Tau3 (Horiba). Each dAb (50 mM) was prepared with and without 5 M guanidine hydrochloride (GuHCl). Intermediate GuHCl concentrations were achieved through mixing the two samples and allowing them to reach equilibrium. The fluorescence was followed at 350 nm (2 nm bandwidth for both excitation and emission), and the recorded intensity values were fit to a two-state cooperative equilibrium model (Santoro and Bolen, 1988) .
Antibody solubility analysis
The native protein solubility was evaluated by preparing each dAb at 55 mM (1Â PBS, pH 7.4), and incubating the samples at 258C for 7 days. Samples of each dAb were collected every 12 h, sedimented (10 000 Â g), and the supernatant concentrations were assayed using the BCA protein assay (Pierce). The non-native protein solubility was evaluated by preparing the dAbs at 15 mM, and then heating them to 60 -958C for 20 min. Afterward, the samples were cooled to 258C for 20 min, and sedimented (1200 Â g). The supernatant concentrations were assayed using the BCA protein assay (Pierce).
Size-exclusion chromatography analysis
Size-exclusion chromatography (SEC) was performed using a Waters 600 high-performance liquid chromatography system and an analytical TSK Gel G3000SWxl column (0.78 Â 30 cm, Tosoh Bioscience). Protein samples were prepared at 25 mM, and injected (100 ml) at a flow rate of 0.5 ml/min. The elution of each dAb was monitored at 280 nm using a Waters 2476 series UV Absorbance detector.
Antibody-binding analysis
The affinities of wild-type and charged Ab dAbs for Ab42 fibrils were measured using competitive enzyme-linked immunosorbent assay analysis (Friguet et al., 1985) . Ab samples (1 -10 mM) were co-incubated overnight with a fixed dAb concentration (1 mM), and the following day the amount of unbound dAb was quantified, as reported previously (Perchiacca et al., 2012a) . The dissociation constants were calculated based on binding measurements for at least five antigen concentrations in excess of the dAb concentration (Friguet et al., 1985) .
The relative-binding affinity of Ab42 dAbs was also evaluated in terms of the IC 50 concentration of dAb binding to immobilized Ab fibrils. Ab fibrils (1.5 mM) were immobilized in 96-well microtiter plates (Nunc Maxisorb, Thermo Fisher), the plates were blocked (10% milk in PBS) and Ab dAbs were added at a range of concentrations (10 -1500 nM). After removal of unbound dAb, the bound antibody was detected via its C-terminal triple FLAG tag using primary (anti-FLAG, Sigma-Aldrich) and appropriate horseradish peroxidase-conjugated secondary antibodies.
The detection sensitivity and binding specificity of the Ab dAbs were also evaluated via immunoblot analysis. Ab42 conformers (25 mM) were assembled as reported previously (Perchiacca et al., 2012a) , diluted and deposited (2 ml) on nitrocellulose membranes (Hybond ECL, GE Healthcare). The blots were blocked (10% milk in PBS), probed with Ab dAbs (6 mM) and then with primary (anti-FLAG, Sigma-Aldrich) and appropriate horseradish peroxidaseconjugated secondary antibodies. After washing, the blots were exposed to substrate (ECL, Western blotting Substrate, Thermo Fisher) and developed.
Results

Hydrophobic CDR3 loops mediate dAb aggregation
The overall aim of this work is to understand how singledomain antibodies with hydrophobic CDR loops can be engineered to resist aggregation without eliminating hydrophobic CDR residues. Therefore, we first evaluated the impact of two hydrophobic Ab peptides (Ab residues 15-QKLVFFAEDV-24 and 33-GLMVGGVVIA-42) within CDR3 of a V H dAb on antibody solubility relative to dAbs presenting hydrophilic Ab peptides (Ab residues 1-DAEFRHDSGY-10 and 21-AEDVGSNKGA-30; Fig. 1 ). We previously reported that the Ab15-24 and Ab33-42 dAbs bearing hydrophobic CDR3 loops bind to Ab fibrils and prefibrillar oligomers with nanomolarbinding affinity, while the Ab1-10 and Ab21-30 dAbs are inactive (Perchiacca et al., 2012a) . Notably, the expression level of the Ab15-24 and Ab33-42 dAbs (5-7 mg/l) is 3-fold lower than for the Ab1-10 and Ab21-30 dAbs (17 -20 mg/l). Nevertheless, the four Ab dAbs possess similar secondary structure ( Supplementary Fig. S1 ), confirming that the different CDR3 sequences weakly influence antibody-folding behavior. However, we find that the Ab15-24 and Ab33-42 dAbs aggregate when heated above 708C, and fail to reversibly unfold ( Fig. 2A and B and Supplementary Fig. S1 ). In contrast, the Ab1-10 and Ab21-30 dAbs are soluble when heated to 958C, and refold without aggregating when cooled to 258C ( Fig. 2A and B and Supplementary Fig. S1 ), as observed for the wild-type dAb (Barthelemy et al., 2008) .
The dramatic difference in solubility between the Ab dAbs presenting hydrophobic and hydrophilic CDRs is not limited to conditions that promote antibody unfolding (Fig. 2C ). We also find that the Ab15-24 and Ab33-42 dAbs aggregate at 258C after 2 days, while the Ab1-10 and Ab21-30 dAbs remain soluble and monomeric for more than 1 week (longer times not evaluated; Fig. 2C and Supplementary Fig. S1 ). Moreover, the Ab15-24 and Ab33-42 dAbs stick to SEC columns and elute as broad peaks, while the Ab1-10 and Ab21-30 dAbs are monomeric and fail to stick to SEC columns (Fig. 2D) . These results collectively demonstrate that hydrophobic CDR3 loops within single-domain antibodies mediate antibody self-association and aggregation.
Charged mutations outside of CDR3 fail to prevent dAb aggregation
We next evaluated the effectiveness of introducing charged mutations into the antibody scaffold to prevent antibody aggregation. Therefore, we simultaneously introduced five negatively charged mutations (L11D, P41D, K43E, S74D and S112D) into the Ab15-24 and Ab33-42 dAbs at the most solvent-exposed positions outside of the CDR loops ( Fig. 3A) , as we and others have reported previously (Perchiacca et al., 2011; Miklos et al., 2012) . This caused the theoretical pI of the wild-type Ab dAbs ( pH 5.1) to decrease to pH 4.6, which we expected to increase antibody solubility due to increased electrostatic repulsion at neutral pH.
Nevertheless, the charged mutations in the antibody scaffold of the Ab15-24 and Ab33-42 dAbs failed to increase their expression level (5 -7 mg/l for both charged and uncharged dAbs). The charged dAbs also possess similar secondary structure and conformational stability relative to their parent dAbs ( Supplementary Fig. S2 ). Most importantly, we find that increasing the net charge of both Ab dAbs modestly increases their solubility when heated above 708C (Fig. 3B) , although the charged variants still partially aggregate upon heating and do not fully refold upon cooling ( Supplementary  Fig. S2 ).
The five charged mutations within the V H scaffold and non-CDR loops also modestly improved the native solubility of the Ab15-24 and Ab33-42 dAbs at 258C (Fig. 3C) . The apparent solubility and time to onset of aggregation were both increased for the charged variants relative to the wildtype dAbs, although the charged mutations fail to eliminate aggregation. In addition, SEC analysis revealed that the charged dAbs also stick to the SEC column, although they display sharper peaks than the wild-type Ab dAbs ( Fig. 3D and E). We conclude that introducing charged mutations into the non-CDR loops and antibody scaffold is an incomplete solution to suppressing antibody aggregation for dAbsbearing hydrophobic CDR loops.
Charged mutations at both edges of CDR3 suppress dAb aggregation
Our findings that preventing aggregation of single-domain antibodies is more difficult than simply increasing the antibody net charge led us to evaluate our main hypothesis that inserting charged residues at the edges of hydrophobic CDR loops will potently inhibit aggregation. We generated variants of the Ab15-24 and Ab33-42 dAbs with single-(Asp), double-(Asp-Asp) and triple-(Asp-Glu-Asp) charged mutations inserted at each edge of the Ab peptide segments within CDR3 (Supplementary Fig. S3 ). The expression of all of the charged variants was 3-fold higher (16 -20 mg/l) than for the parent dAbs (5 -7 mg/l; Table I ), which we suspected was due to the increased solubility of the charged CDR3 dAbs. We confirmed that each CDR3 charged variant possesses similar secondary structure and conformational stability as the parent dAbs (Table I and Supplementary Fig. S4 ).
We next evaluated the impact of inserting negatively charged residues within CDR3 on the non-native solubility of the Ab15-24 and Ab33-42 dAbs ( Fig. 4A and B) . Inserting even a single-charged residue near each edge of CDR3 was more effective at preventing heat-induced aggregation for both the Ab dAbs ( Fig. 4A and B ) than introducing five charged residues in the non-CDR loops (Fig. 3B) . Nevertheless, inserting a single-charged mutation at each edge of CDR3 did not fully suppress aggregation of either Ab dAb. Two (Asp-Asp) or three (Asp-Glu-Asp) charged residues inserted at each edge of CDR3 eliminated aggregation for both dAbs, even when heated to 958C (Fig. 4A and  B) , and enabled the Ab dAbs to fully refold when cooled to 258C (Supplementary Fig. S4 ).
The native solubility of the charged CDR3 variants of the Ab dAbs also increased significantly (Fig. 4C and D and Supplementary Fig. S5 ). A single charge at each edge of CDR3 increased the native solubility of the Ab15-24 and Ab33-42 dAbs, but was modestly less effective than the five charged mutations outside of CDR3 (Fig. 3C) . Two charges at each edge of CDR3 further increased the solubility of the Ab dAbs, and no aggregation was detected for the triple-charged variant after 1 week (longer times not investigated; Fig. 4C  and D) . SEC analysis revealed the charged Ab dAbs eluted as one major peak and one minor peak ( Fig. 4E and F) . The major peak is sharp and runs at the same position as the hydrophilic Ab dAbs (Ab1-10 and Ab21-30), while the minor peak runs after the void volume and appears to be antibody monomer and/or aggregate that sticks to the column. The magnitude of the minor peak decreases with increasing number of charges at each edge of CDR3, which is consistent with the solubility results (Fig. 4A-D) . Our findings reveal that introducing charged insertion mutations at the edges of hydrophobic CDRs is an effective and systematic strategy for preventing antibody self-association and aggregation.
Solubilizing activity of charged mutations at one edge of CDR3 is dependent on the CDR sequence An unexpected finding from our experiments is that charged insertion mutations at the edges of CDR3 adjacent to two different Ab peptide sequences are equally effective at preventing aggregation. This is surprising because the Ab peptide segment within CDR3 of the Ab15-24 dAb (residues 15-QKLVFFAEDV-24) contains three charged residues (Lys 16, Glu 21 and Asp 22), while the Ab segment within CDR3 of the Ab33-42 dAb (Ab residues 33-GLMVGGVVIA-42) is uncharged. Moreover, the Ab33-42 dAb presents its most hydrophobic segment (Ab residues 39-VVIA-42) near the C-terminus of CDR3. In contrast, the Ab15-24 dAb presents its most hydrophobic segment (Ab residues 17-LVFFA-21) near the center of CDR3, and this hydrophobic segment is flanked by charged residues (Lys 16, Glu 21 and Asp 22). Therefore, we hypothesized that inserting charged mutations at only one edge of CDR3 would reveal differences between the two Ab dAbs. We posited that the Ab33-42 dAb would be most soluble if charged residues were inserted near the hydrophobic C-terminus of CDR3. In contrast, we suspected that the solubility of the Ab15-24 dAb would be less dependent on the location of charged mutations within CDR3 due to the central location of its hydrophobic Ab segment (Ab residues 17-21).
To evaluate these hypotheses, we synthesized Ab15-24 and Ab33-42 dAbs with a triad of charged residues (Asp-Glu-Asp) inserted at either the N-or C-terminus of CDR3, which we denote as the N-terminal DED or C-terminal DED variants of each Ab dAb. The expression level of both charged variants of the Ab15-24 dAb (16 -18 mg/l) were similar to that for the Ab15-24 dAb bearing the charged triad near both edges of CDR3 (18 mg/l; Table II ). However, the N-terminal DED variant of the Ab33-42 dAb was expressed at lower levels (6 mg/l) than the C-terminal DED (15 mg/l) and parent (16 mg/l) dAbs. This difference in expression level suggested that the solubility of the N-terminal DED variant of the Ab33-42 dAb may be lower than that of the other charged Ab dAbs. Indeed, we find that only the N-terminal DED variant of the Ab33-42 dAb aggregated when heated ( Fig. 5A and B) , despite that this poorly soluble dAb possesses similar secondary structure and stability as the other charged and wildtype Ab dAbs (Table II and Supplementary Fig. S6 ). This same Ab33-42 dAb (N-terminal DED) also aggregated at 258C after 3 days, while no aggregation was detected at the same conditions for the other charged Ab15-24 and Ab33-42 dAbs (Fig. 5C and D) . As expected, SEC analysis revealed that the N-terminal DED variant of the Ab33-42 dAb forms multimers and sticks to the column, while the other charged variants of the Ab dAbs are largely monomeric and elute at their expected size (Supplementary Fig. S6 ).
These results suggest that the solubilizing activity of charged insertion mutations near the edges of hydrophobic CDRs is dependent on their proximity to the most hydrophobic portion of CDR3. To further test this hypothesis, we sought to evaluate the sensitivity of dAb solubility on the location of CDR3 charged mutations for other Ab dAbs. We identified two additional Ab dAbs that display Ab residues 12-VHHQKLVFFA-21 and 18-VFFAEDVGSN-27 as candidates for these studies because the most hydrophobic portion of these CDR3 loops (Ab residues 18-VFFA-21) is located near the opposite termini of CDR3. We first evaluated whether the wild-type Ab12-21 and Ab18-27 dAbs display similar aggregation propensities as the Ab15-24 and Ab33-42 dAbs (Fig. 6) . We find that the Ab12-21 and Ab18-27 dAbs aggregate within minutes when heated above 708C (Fig. 6A and B) and within 2 days when stored at 258C (Fig. 6C and  D) , as observed for the Ab15-24 and Ab33-42 dAbs (Fig. 2) .
We next evaluated the impact of inserting negatively charged residues (Asp-Glu-Asp) near the N-and/or C-terminal edges of CDR3 for the Ab12-21 and Ab18-27 dAbs (Fig. 6 ). Based on our initial findings for the Ab33-42 dAb, we expected that inserting charged residues near the C-terminus of CDR3 for the Ab12-21 dAb and the N-terminus of CDR3 for the Ab18-27 dAb would eliminate aggregation, while inserting charges at the opposite termini of CDR3 would fail to prevent dAb aggregation. Consistent with this hypothesis, we observed higher expression yields for Ab dAbs bearing charged residues adjacent to the most hydrophobic portion of their CDR3 loops (16 -17 mg/l) relative to dAbs bearing charged residues at the opposite CDR3 termini (6-7 mg/l) and the wild-type Ab dAbs (6 mg/l; Table III ). These differences in expression did not impact the secondary structures and stabilities of the Ab dAbs (Table III and Supplementary Fig. S7 ). We also find that the location of the charged insertion mutations differentially impacts the solubility of the Ab12-21 and Ab18-27 dAbs (Fig. 6) . The N-terminal DED Ab12-21 and C-terminal DED Ab18-27 dAbs readily aggregate when heated above 708C, while the other dAbs bearing charged insertion mutations near the opposite termini of CDR3 (C-terminal DED Ab12-21 and N-terminal DED Ab18-27) or near both CDR3 termini resist aggregation when heated to 958C (Fig. 6A and B) . The dAbs that aggregate within minutes when heated (N-terminal DED Ab12-21 and C-terminal DED Ab18-27 dAbs) also aggregate within days when stored at 258C, while the other Ab12-21 and Ab18-27 dAb variants are soluble and monomeric for a week (longer times not evaluated; Fig. 6C and D) . These findings strongly suggest that the solubilizing activity of charged mutations within antibody CDRs is directly related to their proximity to clusters of hydrophobic residues.
CDR3-charged mutations do not alter binding affinity
We posited that charged insertion mutations at the edges of CDRs-which do not eliminate residues from CDR loopswould have minimal impact on the binding affinity of the Ab dAbs. Therefore, we evaluated the binding affinity of the Ab15-24 and Ab33-42 dAbs bearing single-(Asp), double-(Asp-Asp) and triple-(Asp-Glu-Asp) charged residues near each edge of CDR3. We find that the dissociation constants and IC 50 values for each of the charged dAbs binding to Ab fibrils are indistinguishable relative to the uncharged parent dAbs (Table IV) .
We also used immunoblot analysis to evaluate the conformational specificity and detection sensitivity of the wild-type and charged variants of the Ab15-24 and Ab33-42 dAbs (Fig. 7) . We reported previously that the Ab15-24 dAb binds to Ab fibrils but not to Ab monomers or prefibrillar soluble oligomers Apparent melting temperature (antibodies aggregated irreversibly upon unfolding). (Perchiacca et al., 2012a) . In contrast, we found that the Ab33-42 dAb binds not only to Ab fibrils, but also to Ab prefibrillar soluble oligomers and Ab monomers (albeit with reduced affinity). Consistent with these previous results, we find that the each charged variant of the Ab15-24 dAb binds to Ab fibrils with the same detection sensitivity as the wild-type Ab15-24 dAb (Fig. 7) . In contrast, the charged Ab33-42 dAb variants bind to the three Ab conformers with unique detection sensitivities that are indistinguishable to those of the wild-type Ab33-42 dAb. We conclude that charged insertion mutations near the edges of CDR3 dramatically increase the solubility of single-domain antibodies without reducing their binding affinity or altering their binding specificity.
Discussion
Our experiments have yielded some of the most detailed and systematic insights to date on how to engineer domain antibodies to resist aggregation without reducing their binding affinity. This is due to several unique features of the Ab dAbs studied in this work. First, the CDR residues that contact the antigen (Ab) for each dAb are contained within a single CDR loop (CDR3). This enabled us to insert charged residues near the edges of CDR3 with minimal concern of how such charged mutations change the position of CDR3 relative to the other CDR loops. A second unique aspect of the Ab dAbs is that their hydrophobic residues mediating aggregation are also contained in a single CDR loop. This enabled us to insert charged residues in a systematic manner at the edges of the hydrophobic CDR to evaluate their impact on solubility, which would be more complicated if clusters of hydrophobic residues were located in multiple CDRs. A third unique aspect of the Ab dAbs is that they display unusually hydrophobic peptide segments that serve as a worst case scenario for the type of hydrophobic clusters found within CDRs of conventional antibody fragments and full-length antibodies. The extreme hydrophobicity of these CDR3 loops enabled us to elucidate systematic strategies for preventing aggregation of domain antibodies that can be readily adapted for less hydrophobic CDRs by inserting fewer charged residues at the edges of CDR loops. Given these differences between the Ab dAbs studied in this work and conventional antibodies, it is likely that inserting multiple charged mutations at the edges of CDRs will reduce binding affinity for antibodies that contact antigens via multiple CDR loops. Nevertheless, we find that inserting even a single-charged residue at each edge of CDR3 significantly reduces the aggregation of dAbs bearing extremely hydrophobic CDR3 loops. This is important because conventional antibodies typically do not contain CDR loops that are as hydrophobic as the ones investigated in this work. Therefore, it is possible that introducing single charged mutations at one or both edges of CDRs-either by insertion or substitution-would improve the solubility of conventional antibodies without significantly reducing antibody-binding affinity. More importantly, our findings could be readily incorporated into the design of new synthetic antibody libraries that contain randomized positions within the middle of CDRs to confer binding activity and conserved positions at the edges of CDRs bearing charged residues to confer high solubility.
While it is widely recognized that charged residues improve protein solubility, our findings confirm the critical importance of the location of such mutations on their solubilizing activity (Jespers et al., 2004b; Barthelemy et al., 2008; Famm et al., 2008; Perchiacca et al., 2011) . Our results demonstrate that the solubility of domain antibodies bearing extremely hydrophobic CDR loops is strongly dependent on the proximity of charged residues to clusters of hydrophobic residues. Not only did we find that charged mutations outside of CDR3 are unable to fully suppress aggregation, but we also found that the location of charged mutations within CDR3 (either at the N-or C-terminus of CDR3) significantly impacts antibody solubility. The results for the Ab12-21 and Ab18-27 dAbs provide a dramatic demonstration of how charged residues must be located at specific termini of CDR3 Fig. 7 . Effect of charged mutations inserted at both edges of CDR3 on the detection sensitivity and specificity of the Ab15-24 and Ab33-42 dAbs. Ab42 conformers were deposited on nitrocellulose membranes (0.9-220 ng), and probed with Ab dAbs (6 mM). The blots were also probed with sequence-specific (6E10, specific for Ab residues 3-10) and conformation-specific polyclonal antibodies (OC, specific for fibrils; A11, specific for prefibrillar soluble oligomers).
to counter the insolubility conferred by solvent-exposed hydrophobic residues. The simplicity of our findings suggests that attempts to re-engineer antibodies to suppress aggregation should focus on introducing charged mutations near the edges of CDRs closest to the most hydrophobic regions. We expect that algorithms originally developed to identify regions within amyloid-forming proteins that mediate aggregation (Linding et al., 2004; Conchillo-Sole et al., 2007; Trovato et al., 2007; Maurer-Stroh et al., 2010; Goldschmidt et al., 2011) will be useful for identifying aggregation hotspots within CDR loops and for guiding protein engineering effects to systematically introduce solubilizing mutations at the edges of hydrophobic CDRs. The mechanism used by charged Ab dAbs to avoid aggregation without reducing binding affinity deserves further consideration. For the non-charged Ab dAbs, we posit that the grafted Ab motifs mediate dAb self-association and aggregation via self-complementary interactions in a manner similar to how these motifs mediate Ab amyloid formation (Petkova et al., 2002; Luhrs et al., 2005) . This hypothesis would suggest that electrostatic repulsion between negatively charged mutations within CDR3 disrupts self-association of the grafted Ab motifs, thereby preventing dAb aggregation. We also hypothesize that the binding affinity of charged Ab dAbs is unchanged relative to the wild-type dAbs because Ab fibrils lack clusters of negatively charged residues at positions that are charged within CDR3. Thus, we expect that intermolecular interactions between dAbs and Ab fibrils lack the repulsive electrostatic interactions that prevent self-association of Ab dAbs, resulting in similar binding affinity for charged and uncharged Ab dAbs.
An important finding of our work is that the conformational stability of Ab dAbs is uncorrelated with their aggregation propensity, as observed for other aggregation-resistant dAbs (Ewert et al., 2002; Jespers et al., 2004a,b; Perchiacca et al., 2011) . Our findings reveal that charged mutations at the edge of CDR3 do not improve solubility by preventing antibody unfolding, but rather by inhibiting attractive intermolecular interactions between hydrophobic antibody loops. Moreover, hydrophobic clusters within CDR3 of the Ab dAbs are solvent exposed even when the antibody is folded, which eliminates the need for the dAbs to unfold to become competent for aggregation. While it is unlikely that multidomain antibodies such as Fabs and IgGs will be able to reversibly unfold when heated as we observed for some of the charged Ab dAbs, we expect that similar charged mutations as those investigated in this work will improve the native solubility of multidomain antibodies. It will be important in the future to evaluate if the CDRs of multidomain antibodies can be engineered to prevent antibody aggregation without reducing their binding affinity using systematic methods such as those reported in this work.
Another outstanding question is whether inserting positively charged mutations within hydrophobic CDRs of Ab dAbs will be as effective at suppressing aggregation as negatively charged mutations. Multiple studies have found that aggregation-resistant dAbs typically are more negatively charged than their aggregation-prone counterparts, and these highly soluble dAbs are enriched in negatively charged residues inside and outside the CDR loops (Jespers et al., 2004a (Jespers et al., 2004b; Famm et al., 2008) , and single-chain variable fragments (scFvs) that are 'supercharged' with positively charged mutations (up to 25 mutations) are more soluble than their negatively charged counterparts (Miklos et al., 2012) . We expect that additional mutational analysis of Ab dAbs in which each charged amino acid is individually inserted near hydrophobic Ab motifs will provide valuable insights into how amino acid polarity and identity impact antibody solubility, which is currently underway in our laboratory.
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